The SOUL trial (NCT03914326), investigated the effects of oral semaglutide on major adverse cardiovascular events (MACE) in patients with T2D, with or without the use of SGLT2i
At Week 56, treatment with SAXENDA resulted in statistically significant reduction in BMI SDS from baseline compared to placebo
279 The phase 3 HELIOS-B trial (NCT04153149), a multicenter, double-blind, randomized controlled trial, recently reported that vutrisiran reduced the primary endpoint, a composite of all-cause mortality and recurrent cardiovascular events, by 28% in the overall population and by 33% in the monotherapy subgroup
1 2 "Glutathione transferases are structural and functional outliers in the thioredoxin fold"
Tirzepatide (Zepbound): Showed up to 20.9% average weight reduction at the highest dose in the SURMOUNT-1 trial
Approved dosage levels: Titration: Start at 2.5 mg for 4 weeks, then increase gradually based on response.[assets.ctfassets] Where Should I Inject Tirzepatide